Critical Path Institute Takes the Lead in Accelerating Drug Development for Mitochondrial and Inherited Metabolic Diseases with New Task Force

C-Path has initiated a task force dedicated to accelerating drug development for mitochondrial and inherited metabolic diseases. Leveraging their demonstrated expertise, particularly in rare and pediatric indications, C-Path aims to utilize the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®) to integrate diverse patient-level data sources.

This collaborative effort provides a neutral environment for industry, regulatory agencies, academia, and the patient community to actively contribute to advancing solutions and facilitating therapeutic developments for these specific medical conditions.